An experimental treatment, gantenerumab, failed to help people at high risk of memory loss from Alzheimer’s or those who were in the early phases of the disease, the manufacturer said Monday.
Create an account
Welcome! Register for an account
A password will be e-mailed to you.
Password recovery
Recover your password
A password will be e-mailed to you.
Experimental therapy gantenerumab fails to slow or improve Alzheimer’s memory loss in clinical trials
Date:
